AWA
LXRX icon

Arkadios Wealth Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Arkadios Wealth Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed -$196 – 1058
2020
Q2 		$196 Hold
100
– – ﹤0.01% 931
2020
Q1 		$195 Hold
100
– – ﹤0.01% 1088
2019
Q4 		$300 Buy
+100
New +$385 ﹤0.01% 953

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Arkadios Wealth Advisors's LXRX Position: Q3 2020 in Review

Arkadios Wealth Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2020, closing a stake of 100 shares — an estimated $196 sold.

Arkadios Wealth Advisors first reported a position in LXRX in Q4 2019 and held it in 3 quarters. The position peaked at $300 in Q4 2019. 91 funds tracked by Wall St. Rank hold LXRX as of Q3 2020.

  • Arkadios Wealth Advisors reported no remaining Lexicon Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Arkadios Wealth Advisors sold 100 Lexicon Pharmaceuticals shares in Q3 2020, an estimated $196.
  • Arkadios Wealth Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • Arkadios Wealth Advisors's Lexicon Pharmaceuticals position peaked at $300 in Q4 2019.
  • 91 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2020.

Based on Arkadios Wealth Advisors's 13F filing for Q3 2020, filed 10 Nov 2020.